Drugs / INM005
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04494984 Comparator | Jul → Nov 2020 | COVID-19 | Inmunova S.A. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INM005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04494984 ↗ |
| Route | Intravenous | “Subjects will receive a 1st intravenous dose of 4 mg/kg INM005” NCT04494984 ↗ |